Table 1.
Participant demographics, cognitive scores, and neuropathology scales
| N = 350 | |
|---|---|
|
| |
| Demographics | |
| Age at Visit (years) | 85.9 (6.4) |
| Female | 141 (40.3%) |
| Time-to-Death (years) | 1.53 (1.0) |
| Education (years) | 14.7 (3.2) |
| APOE ε4 carrier status | 95 (27.1%) |
| Body mass index | 27.8 (5.9) |
| Time from plasma biomarker collection to death (years) | 1.53 (1.01) |
| Cognitive status | |
| Mayo-PACC Cognitive Score | −0.56 (1.0) |
| Cognitively unimpaired | 197 (56.3%) |
| Mild cognitive impairment | 93 (26.6%) |
| Dementia | 56 (16.0%) |
| Other | 3 (0.9%) |
| Plasma biomarkers | |
| Aβ42/40 ratio | 0.06 (0.01) |
| GFAP (pg/mL) | 208.1 (113.1) |
| NfL (pg/mL) | 62.0 (42.6) |
| P-tau181 (pg/mL) | 3.96 (2.7) |
| Braak Tangle Stages | |
| 0–III | 211 (61.9%) |
| IV–VI | 130 (38.1%) |
| Neuritic Plaque Score | |
| None/sparse | 193 (55.5%) |
| Moderate/frequent | 155 (44.5%) |
| Thal amyloid phase | |
| Thal phase 0–2 | 133 (48.2%) |
| Thal phase 3–5 | 143 (51.8%) |
| ADNC | |
| None/low | 176 (55.7%) |
| Intermediate/high | 140 (44.3%) |
Mean (SD) listed for continuous variables and count (%) for the categorical variables